ANI Prescription drugs, Inc. (ANIP) Presents at forty fourth Annual J.P. Morgan Healthcare Convention Transcript

Ekaterina Knyazkova
JPMorgan Chase & Co, Analysis Division

Hey, everyone. I am Ekaterina Knyazkova from JPMorgan and happy to be introducing ANI Prescription drugs. And from the corporate, we’ve Nikhil Lalwani, CEO; and Steve Carey, CFO, who might be doing a presentation, after which we’ll leap into Q&A. And with that, I’ll flip it over to Nikhil.

Nikhil Lalwani
President, CEO & Director

Good afternoon, and thanks for becoming a member of us right here for a session on ANI Prescription drugs. These are our normal disclaimers concerning forward-looking statements, type of the monetary data that we’re presenting. So I am proud to inform you right here about ANI Prescription drugs, a worthwhile, high-growth biopharmaceutical group. that we’re remodeling into a number one uncommon illness firm. As we undergo the presentation, I will inform you about how we’re accelerating this transformation into a number one uncommon illness firm.

In ’26 we’re projecting over $1 billion of income, which represents 26% development year-on-year versus ’25, a yr might be delivered higher than 39% year-over-year development. The uncommon illness enterprise is our major focus and can account for about 60% of complete revenues. With our lead asset, purified Cortrophin Gel offering substantial sturdy multiyear development alternatives. Our generics enterprise delivered robust money flows pushed by superior R&D capabilities, operational execution and U.S. manufacturing. And what you see on the right-hand facet is that this creates a virtuous cycle of development the place our EBITDA and money flows from generics and types permits us to spend money on uncommon illness and increasing the scope and scale of our uncommon illness enterprise and are accelerating the transformation into changing into a number one uncommon illness